Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
about
Preclinical validation of interleukin 6 as a therapeutic target in multiple myelomaIdentification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screeningInterleukin-6 in bone metastasis and cancer progression.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.Impact of interleukin-6 in hematological malignancies.2-Methoxystypandrone inhibits signal transducer and activator of transcription 3 and nuclear factor-κB signaling by inhibiting Janus kinase 2 and IκB kinaseEmerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesThe novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Environmental-mediated drug resistance: a target for multiple myeloma therapy.Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells.Cyclophilin A as a downstream effector of PI3K/Akt signalling pathway in multiple myeloma cells.Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell supportOvercoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcomaGene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.Mouse models of multiple myeloma: technologic platforms and perspectives.The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
P2860
Q27027729-222543D9-8D1C-47DF-A8C7-7659E6612344Q33616659-0273BB2B-B34B-416F-BA0B-3BD42F17A61BQ34051820-A1424062-AB45-4016-9905-06BC2D409BEFQ34194704-72D25FB4-DD08-4E32-9126-2727F2F4D85DQ34387624-81304CA9-4C09-47FF-AA31-CE8D7F8AA543Q35051465-6821137F-FD22-4FBA-ABEE-070A7A9C49F4Q35132241-16BAEA91-4158-404D-8E59-481B8365AA45Q35551777-9422315F-BD5A-4106-8684-AC87E9990916Q37597751-D234F4A4-1A03-4DE5-9CE2-8AF18BF7C583Q37697253-ACCA873A-D80E-439E-B81F-7BD07CAD4B43Q37810085-002937C8-853A-468C-B31D-8A59FCF0953AQ38016511-315D25B1-3783-4716-97B6-BC47A6917F02Q38044736-F7D69594-0FA3-4E97-BFE0-351FC9551994Q38476564-26CD1489-9B79-4B94-B649-FC21064ABE8DQ38710784-1D7031A2-06CA-4B3C-8013-A337A05C51DCQ38797470-A1B338F9-E94C-4EF3-AA20-181FED91E605Q38854653-9022EE8A-E990-47B8-A6E1-CA87305A1DC9Q39571840-88FB206E-DB98-4C8B-9595-D99F939ED74EQ39752237-E8BBFD58-1D01-4E20-BC35-66E73C153328Q40996325-392267A0-5F5E-4FFF-8EA5-7A5C0A704DA2Q42094834-7D11145C-242E-46E0-90B0-9223A9E321DAQ42725814-860D9C7B-ACCE-4834-8654-7CADDC82C8B4Q50054859-8EB6BE77-29B8-4510-9229-D0D804E31A6AQ54571865-3A2CBAC1-30BA-48AA-AA7E-7F3CA954E896Q55038802-17A6F346-63DA-44BC-91A2-405F7D8BA5BEQ58742654-EE721E38-BB75-4B8F-A630-BA0F0CB5CC8D
P2860
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Janus kinase inhibitor INCB20 ...... ma cells in vitro and in vivo.
@en
Janus kinase inhibitor INCB20 ...... ma cells in vitro and in vivo.
@nl
type
label
Janus kinase inhibitor INCB20 ...... ma cells in vitro and in vivo.
@en
Janus kinase inhibitor INCB20 ...... ma cells in vitro and in vivo.
@nl
prefLabel
Janus kinase inhibitor INCB20 ...... ma cells in vitro and in vivo.
@en
Janus kinase inhibitor INCB20 ...... ma cells in vitro and in vivo.
@nl
P2093
P2860
P1476
Janus kinase inhibitor INCB20 ...... ma cells in vitro and in vivo.
@en
P2093
Claire L Neilan
Dharminder Chauhan
Eian Caulder
Jordan S Fridman
Klaus Podar
Kris Vaddi
Laurence Catley
Martin Gramatzki
Paola Neri
P2860
P356
10.1158/1535-7163.MCT-08-0149
P577
2009-01-01T00:00:00Z